Aurora Cannabis Inc. has announced its financial results for the second quarter of fiscal 2027, highlighting a substantial increase in international medical cannabis revenue. This comes amid the company's recent agreement to be acquired by Organigram Global Inc. The acquisition is poised to reshape the competitive landscape in the medicinal cannabis sector.

For the quarter ending September 30, 2026, Aurora reported net revenue of $86.0 million, which includes a record international medical cannabis revenue of $61.4 million, reflecting a 44% year-over-year increase. This growth is particularly notable as the company has been transitioning its focus towards medical cannabis, moving away from the consumer segment.

The filing, submitted on November 5, 2026, reveals that the company has canceled its investor call scheduled for November 12, 2026, in light of the acquisition announcement made on November 3, 2026. Under the terms of the Arrangement Agreement, Organigram will acquire all outstanding shares of Aurora, offering either C$7.80 in cash, a combination of cash and shares, or shares alone.

Aurora Cannabis Inc., a prominent player in the medicinal chemicals and botanical products industry, has been actively restructuring its operations. The company is listed on both NASDAQ and TSX under the ticker ACB and operates primarily out of Edmonton, Alberta. The recent filing indicates that Aurora is maintaining a strong balance sheet with $133 million in cash and no debt, which may be attractive to Organigram as it moves forward with the acquisition.

The second quarter results also show an improved adjusted EBITDA of $14.0 million, although this is down from $15.4 million in the prior year. The company reported a net loss from continuing operations of $21.1 million, an improvement from the $27.2 million loss reported a year earlier.

As the acquisition process unfolds, it is expected to be completed by January 2027, pending shareholder and regulatory approvals. The merger could lead to significant changes in how both companies operate, potentially influencing pricing strategies and market share within the medicinal cannabis industry.

The filing does not specify what happens next beyond the expected completion of the acquisition. However, further details regarding the transaction will be made available in a joint information circular to be filed on SEDAR+ and EDGAR.